• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Post Menopausal Osteoporosis - Pipeline Review, H2 2012 Product Image

Post Menopausal Osteoporosis - Pipeline Review, H2 2012

  • Published: October 2012
  • 82 pages
  • Global Markets Direct

Post Menopausal Osteoporosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Post Menopausal Osteoporosis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post Menopausal Osteoporosis.
- A review of the Post Menopausal Osteoporosis READ MORE >

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Post Menopausal Osteoporosis Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Post Menopausal Osteoporosis 9
Post Menopausal Osteoporosis Therapeutics under Development by Companies 11
Post Menopausal Osteoporosis Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Post Menopausal Osteoporosis Therapeutics – Products under Development by Companies 18
Post Menopausal Osteoporosis Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Post Menopausal Osteoporosis Therapeutics Development 20
Amgen Inc. 20
Merck & Co., Inc. 21
Ablynx 22
Pfizer Inc. 23
Zydus Cadila Healthcare Limited 24
Unigene Laboratories, Inc. 25
PhytoHealth Corporation 26
Zealand Pharma A/S 27
EffRx, Inc. 28
Radius Health, Inc. 29
EndoCeutics, Inc. 30
Post Menopausal Osteoporosis – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
romosozumab - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
odanacatib - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
alendronate sodium - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
PTH Analogs - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
calcitonin - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Aprela - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ALX-0141 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ZP-2307 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Parathyroid Hormone-Related Protein (1-36) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
lasofoxifene tartrate - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PHN-031 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Denosumab + Teriparatide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
teriparatide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
PTH 1-34 + Fluoride - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
teriparatide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
fluoride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
teriparatide - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Femivia - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates 63
Post Menopausal Osteoporosis Therapeutics – Discontinued Products 72
Post Menopausal Osteoporosis Therapeutics - Dormant Products 73
Post Menopausal Osteoporosis – Product Development Milestones 74
Featured News & Press Releases 74
Sep 27, 2012: Radius Health Initiates Phase II Study Of BA058-Transdermal For Treatment Of Postmenopausal Osteoporosis 74
Jul 19, 2012: EMA Accepts Regulatory Submission For Pfizer's Bazedoxifene/Conjugated Estrogens For Treatment Of Symptoms Associated With Menopause And Osteoporosis 74
Jun 28, 2012: Unigene Announces Presention Of Oral PTH Phase II Proof-Of-Concept Data At Upcoming Scientific Conferences 75
Jun 07, 2012: Roche's Injectable Bone-Strengthening Drug In Short Supply, FDA Says 75
Apr 18, 2012: Merck Wins Another FOSAMAX State Court Trial 76
Apr 04, 2012: UCB And Amgen Initiate Sclerostin Antibody Phase III Program In Patients With Postmenopausal Osteoporosis 77
Mar 21, 2012: Tarsa Therapeutics Signs Commercial Supply Agreement For Ostora Oral Calcitonin Product With QS Pharma 77
Feb 29, 2012: Amgen's Prolia To Be Made Available To Patients In Ontario Through Public Drug Plan 78
Feb 27, 2012: Merck Issues Statement On FOSAMAX Product Liability Trial In New Jersey 79
Dec 20, 2011: Takeda Announces Acceptance Of Steovess For National Approvals In EU 80
Appendix 81
Methodology 81
Coverage 81
Secondary Research 81
Primary Research 81
Expert Panel Validation 81
Contact Us 82
Disclaimer 82

List of Tables
Number of Products Under Development for Post Menopausal Osteoporosis, H2 2012 9
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Amgen Inc., H2 2012 20
Merck & Co., Inc., H2 2012 21
Ablynx, H2 2012 22
Pfizer Inc., H2 2012 23
Zydus Cadila Healthcare Limited, H2 2012 24
Unigene Laboratories, Inc., H2 2012 25
PhytoHealth Corporation, H2 2012 26
Zealand Pharma A/S, H2 2012 27
EffRx, Inc., H2 2012 28
Radius Health, Inc., H2 2012 29
EndoCeutics, Inc., H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates 63
Post Menopausal Osteoporosis Therapeutics – Discontinued Products 72
Post Menopausal Osteoporosis Therapeutics – Dormant Products 73

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H2 2012 9
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos